COMMUNIQUÉS West-GlobeNewswire

Allergy Therapeutics: Trading Update

31/01/2018 - 13:00

Allergy Therapeutics plc ("Allergy Therapeutics" or the "Group") Trading Update Market share gains driving top line growth Strong cash position sustained by good performance. 31 January 2017 Allergy Therapeutics plc ( [...]

Microbot Medical Inc. to Initiate Townhall Meetings

31/01/2018 - 13:00

HINGHAM, Mass., Jan. 31, 2018 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT ), a medical device company specializing in the design and development of transformational micro-robotic medical technologies, today [...]

Cara Therapeutics Initiates Pivotal Phase 3 Efficacy Trial of KORSUVA™ (CR845/difelikefalin) Injection in Hemodialysis Patients with Chronic Kidney Disease-Associated Pruritus

31/01/2018 - 13:00

STAMFORD, Conn., Jan. 31, 2018 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA ), a biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pruritus and [...]

Revive Therapeutics Submits Cannabinoid Delivery Technology Findings Abstract for 29th International Conference on Polyphenols and the 9th Tannin Conference

31/01/2018 - 13:00

TORONTO, Jan. 31, 2018 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (" Revive " or the " Company ") (TSX VENTURE:RVV) (OTCQB:RVVTF), a company focused on the research, development and commercialization of novel [...]

MediciNova Announces Presentation of the SPRINT-MS Phase 2b Study of MN-166 (ibudilast) in Progressive MS at the ACTRIMS Forum on February 1, 2018 in San Diego

31/01/2018 - 13:00

LA JOLLA, Calif., Jan. 31, 2018 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ: MNOV ) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875 [...]

Clementia Appoints Industry Veteran Pierre Legault to its Board of Directors

31/01/2018 - 12:30

MONTREAL, Jan. 31, 2018 (GLOBE NEWSWIRE) -- Clementia Pharmaceuticals Inc. (NASDAQ: CMTA ), a clinical-stage biopharmaceutical company innovating new treatments for people with ultra-rare bone disorders and other [...]

Clementia nomme Pierre Legault, un vétéran de l’industrie, au sein de son conseil d’administration

31/01/2018 - 12:30

MONTRÉAL, 31 janv. 2018 (GLOBE NEWSWIRE) -- Clementia Pharmaceuticals Inc. (NASDAQ: CMTA ), une société biopharmaceutique au stade clinique proposant des traitements novateurs pour les personnes atteintes de troubles [...]

Novo Nordisk A/S - Share repurchase programme

31/01/2018 - 12:00

Bagsværd, Denmark, 31 January 2018 - On 1 November 2017, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No. 596/2014 of the European Parliament and Council of 16 April [...]

BeiGene Initiates Global Phase 3 Trial of Anti-PD-1 Antibody Tislelizumab in Patients with Esophageal Squamous Cell Carcinoma

31/01/2018 - 12:00

CAMBRIDGE, Mass. and BEIJING, China, Jan. 31, 2018 (GLOBE NEWSWIRE) -- BeiGene, Ltd. (NASDAQ: BGNE ), a commercial-stage biopharmaceutical company focused on developing and commercializing innovative molecularly [...]

Green Cures & Botanical Distribution Inc. Begins Building E-Commerce Site, Working on New Packaging, and Developing New Products

31/01/2018 - 11:30

LOS ANGELES, CA, Jan. 31, 2018 (GLOBE NEWSWIRE) -- Green Cures and Botanical Distribution Inc. (OTC PINK: GRCU), an innovative hemp-infused nutrition, botanical, sports, and body care products company, has engaged a web [...]

Results from 31 January 2018 General Meeting

31/01/2018 - 11:00

MELBOURNE, Australia, Jan. 31, 2018 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (ASX:GTG) (NASDAQ: GENE ) (“Company”) advises that a General Meeting of shareholders that had been requisitioned pursuant to section [...]

Michaela Gertz Joins Immunicum as CFO

31/01/2018 - 09:45

Press Release 31 January 2018 Michaela Gertz Joins Immunicum as CFO Immunicum AB (publ; Nasdaq Stockholm: IMMU.ST) a biopharmaceutical company advancing a novel, immune-priming cancer treatment against a variety of [...]

MPI's spinout Oncology Venture announces positive interim results from a Phase 1/2 DRP guided study of LiPlaCis in heavily pretreated breast cancer patients

31/01/2018 - 09:31

Hoersholm, Denmark, January 31, 2018 - Medical Prognosis Institute A/S (MPI.ST) spinout Oncology Venture AB (OV:ST) today announces the second interim report from the Phase 2 part of an ongoing LiPlaCis® Phase 1/2 study [...]

C-RAD AB – Consolidated Year-End report January-December 2017

31/01/2018 - 08:30

POSITIVE RESULT FOR THE FOURTH QUARTER 2017 Key events in the period October - December 2017 FOURTH QUARTER 2017 Order intake: 47.5 (41.9) MSEK, +13%. Revenues: 42.0 (27.3) MSEK, +54%. Operating profit: 1.1 (-4.4) MSEK [...]

Ambu A/S: Interim report Q1 2017/18

31/01/2018 - 08:05

Ambu has had a good start to the year with organic growth of 14%, an almost 4 percentage point improvement in the EBIT margin to 16.5% and free cash flows of DKK 36m. Our outlook on earnings and free cash flows for the [...]

Sanofi: Sanofi, DNDi seek European Medicines Agency review for sleeping sickness treatment

31/01/2018 - 08:01

Press Release Source: Sanofi (EURONEXT: SAN) (NYSE: SNY) Sanofi, DND i seek European Medicines Agency review for sleeping sickness treatment Fexinidazole would be first all-oral treatment* under investigation for both [...]

Sanofi et la DNDi soumettent une demande d'approbation de leur traitement contre la maladie du sommeil à l'Agence européenne des médicaments

31/01/2018 - 08:01

Communiqué de presse Source : Sanofi (EURONEXT: SAN) (NYSE: SNY) Sanofi et la DND i soumettent leur traitement contre la maladie du sommeil à l'évaluation de l'Agence européenne des médicaments Le féxinidazole serait le [...]

Change in the Number of Shares and Votes in Immunicum

31/01/2018 - 08:01

Press Release 31 January 2018 Change in the Number of Shares and Votes in Immunicum Immunicum AB (publ; IMMU.ST) a biopharmaceutical company advancing a novel, immune-priming cancer treatment against a variety of solid [...]

ESPERITE (ESP) : L1 Capital subscribes to the 14th tranche of investment today

31/01/2018 - 07:17

Amsterdam, The Netherlands - 31 January 2018 Esperite N.V. (Euronext: ESP, "Esperite" or "the Group") announces that today the 14 th Tranche of EUR 250,000 is issued as a private placement of 25 convertible notes (the " [...]